These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35706353)

  • 1. Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres.
    Wissmüller M; Xanthouli P; Benjamin N; Grünig E; Richter MJ; Gall H; Ghofrani HA; Herkenrath S; Skowasch D; Pizarro C; Halank M; Hohmann C; Hellmich M; Gerhardt F; Rosenkranz S
    ESC Heart Fail; 2022 Oct; 9(5):2873-2885. PubMed ID: 35706353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Management of Patients with Pulmonary Arterial Hypertension: Insights from EXPOSURE.
    Muller A; Escribano-Subias P; Fernandes CC; Fontana M; Lange TJ; Söderberg S; Gaine S
    Adv Ther; 2024 Mar; 41(3):1103-1119. PubMed ID: 38216826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of rapid sequential combination therapy on distinct haemodynamic measures in newly diagnosed pulmonary arterial hypertension.
    Kramer T; Nattmann P; Gerhardt F; Stafiej P; Dumitrescu D; Ten Freyhaus H; Wißmüller M; Hohmann C; Baldus S; Rosenkranz S
    ESC Heart Fail; 2024 Jun; 11(3):1540-1552. PubMed ID: 38224960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?
    Moonen A; Garsia R; Youssef P; Torzillo P; Corte T; Boehm C; Cordina R; Celermajer D; Lau E
    Intern Med J; 2017 Oct; 47(10):1124-1128. PubMed ID: 28560817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy in patients with pulmonary arterial hypertension at four German PH centres.
    Stubbe B; Seyfarth HJ; Kleymann J; Halank M; Al Ghorani H; Obst A; Desole S; Ewert R; Opitz CF
    BMC Pulm Med; 2021 Apr; 21(1):130. PubMed ID: 33882879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
    Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
    Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry.
    Garcia AR; Blanco I; Ramon L; Pérez-Sagredo J; Guerra-Ramos FJ; Martín-Ontiyuelo C; Tura-Ceide O; Pastor-Pérez F; Escribano-Subías P; Barberà JA
    Respir Res; 2023 Sep; 24(1):223. PubMed ID: 37715261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study.
    Pestaña-Fernández M; Rubio-Rivas M; Tolosa-Vilella C; Guillén-Del-Castillo A; Freire M; Vargas-Hitos JA; Todolí-Parra JA; Rodríguez-Carballeira M; Marín-Ballvé A; Espinosa G; Colunga-Argüelles D; Ortego-Centeno N; Trapiella-Martínez L; Carbonell-Muñoz C; Pla-Salas X; Perales-Fraile I; Corbella X; Fonollosa-Pla V; Simeón-Aznar CP;
    J Rheumatol; 2020 Jan; 47(1):89-98. PubMed ID: 30770503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.
    Small M; Piercy J; Pike J; Cerulli A
    Adv Ther; 2014 Feb; 31(2):168-79. PubMed ID: 24449285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era.
    Gerhardt F; Fiessler E; Olsson KM; Kayser MZ; Kovacs G; Gall H; Ghofrani HA; Badr Eslam R; Lang IM; Benjamin N; Grünig E; Halank M; Lange TJ; Ulrich S; Leuchte H; Held M; Klose H; Ewert R; Wilkens H; Pizarro C; Skowasch D; Wissmüller M; Hellmich M; Olschewski H; Hoeper MM; Rosenkranz S
    Circulation; 2024 May; 149(20):1549-1564. PubMed ID: 38606558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
    Badagliacca R; D'Alto M; Ghio S; Argiento P; Bellomo V; Brunetti ND; Casu G; Confalonieri M; Corda M; Correale M; D'Agostino C; De Michele L; Galgano G; Greco A; Lombardi C; Manzi G; Mercurio V; Mulè M; Paciocco G; Papa S; Romeo E; Scelsi L; Stolfo D; Vitulo P; Naeije R; Vizza CD
    Am J Respir Crit Care Med; 2021 Feb; 203(4):484-492. PubMed ID: 32857597
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges.
    Anderson J; Lavender M; Lau E; Celermajer D; Collins N; Dwyer N; Feenstra J; Horrigan M; Keating D; Keogh A; Kotlyar E; Ng B; Proudman S; Steele P; Thakkar V; Weintraub R; Whitford H; Williams T; Wrobel J; Strange G
    Heart Lung Circ; 2020 Oct; 29(10):1459-1468. PubMed ID: 32280014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry.
    Chazova IE; Arkhipova OA; Martynyuk TV
    Ter Arkh; 2019 Mar; 91(1):24-31. PubMed ID: 31090367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation].
    Kaemmerer H; Gorenflo M; Hoeper M; Huscher D; Ewert P; Pittrow D
    Dtsch Med Wochenschr; 2013 Jun; 138(23):1247-52. PubMed ID: 23720182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study).
    Lange TJ; Escribano-Subias P; Muller A; Fernandes CC; Fontana M; Remenova T; Söderberg S; Gaine S
    Adv Ther; 2024 Sep; 41(9):3645-3663. PubMed ID: 39083197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
    Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
    Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.